Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 February 2023 | Story Prof Nicholas Pearce | Photo Andre Damons
The Faculty of Health Sciences and the Faculty of the Humanities at the University of the Free State (UFS), in collaboration with PathCare laboratories, joined forces on Valentine’s Day – since it is seen as a day of unconditional love that you share with your partner – reaching out to the community in the Bloemfontein CBD and Preller Square, by drawing attention to gender-based violence – a topic that is often misunderstood, not discussed, and often occurs behind closed doors.

The University of the Free State views gender-based violence (GBV) as a scourge of our modern society. In this vein, the Faculty of Health Sciences and the Faculty of the Humanities joined forces on Valentine’s Day, since it is seen as a day of unconditional love that you share with your partner.

In collaboration with PathCare laboratories, the university saw an opportunity to reach out to the community in the CBD and Preller Square. The idea was to draw attention to a topic that is often misunderstood, not discussed, and often occurs behind closed doors. Medical and Humanities students actively engaged with the communities by handing out Valentine’s chocolates and information pamphlets regarding GBV.

Community engagement forms part of the UFS’ strategic goals. The collaboration between these two faculties on such an important topic is testament to the university’s commitment to eradicating GBV in all forms and manifestations.

Prof Frans Maruma, Head of the Marketing Committee for the School of Clinical Medicine, stated that “gender-based violence has no place in our modern society. Most of the time, victims are among us and go unrecognised”.

The Faculty of the Humanities provided a visual aspect to this important topic by doing the make-up of the students involved in order to highlight the abuse these victims suffer. Mr Cloete (Faculty of the Humanities) indicated that “no person is immune to gender-based violence, and gender-based violence transcends race, gender, and wealth”.

Pathcare laboratories was proud to collaborate with the University of the Free State, as this aligns with their ideology of community-based care. PathCare recognises its role in the broader society by offering to test victims of GBV. PathCare offers a range of tests, specially catered towards GBV survivors to ensure that appropriate medical care can be provided in the shortest possible turnaround time.

Two thousand chocolates and pamphlets were distributed to members of the community through this collaboration. The university and the private sector hope to eradicate GBV on local and national level. 

Gender-based violence may be any of the following: physical abuse, verbal abuse, psychological abuse, sexual abuse, socio-economic abuse, domestic violence, or abuse such as sexual harassment. Below are the UFS contact details for victims of GBV. 

University of the Free State
Gender Equality and Anti-Discrimination Office (GEADO)

Bloemfontein Campus
Deputy Director: Nchabeleng Lentsu
nchabelengnv@ufs.ac.za

Senior Officer: Geraldine Lengau
Contact: +27 51 401 3982

South Campus
Senior Officer: Mocwana Chelepe
Contact: +27 51 401 7544

Student Counselling and Development (SCD)
Contact: +27 51 401 9236

Victim Empowerment Centre (TCC)
Walk-ins.
 
HOTLINES:
UFS SART (Sexual Assault Response Team) 
+27 57 401 7777

GBVCC (Gender-Based Violence Command Centre)
0800 428 428

Please call me facility:
*120*7867#

Skype line: 
Helpme GBV for members of the deaf community.

An SMS-based line:
31531 for persons with disabilities (SMS ‘help’ to 31531)

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept